A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model

Highlights • DNA vaccine technology fusing cancer antigens to CD40L soluble multi-trimers. • Allows targeting of vaccine antigens to dendritic cells in situ. • Activates and matures dendritic cells. • Vaccine induces an anti-tumor immune response when combined with IL-12 and GM-CSF.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2015-09, Vol.33 (38), p.4798-4806
Hauptverfasser:	Gupta, Sachin, Termini, James M, Rivas, Yaelis, Otero, Miguel, Raffa, Francesca N, Bhat, Vikas, Farooq, Amjad, Stone, Geoffrey W
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - genetics Adjuvants, Immunologic - metabolism Allergy and Immunology Animals Antigens B16-F10 melanoma Cancer Cancer vaccine Cancer Vaccines - administration & dosage Cancer Vaccines - genetics Cancer Vaccines - immunology CD40 Ligand - genetics CD40 Ligand - metabolism CD40L Cytokines Dendritic cell Dendritic cells Dendritic Cells - immunology Deoxyribonucleic acid Disease Models, Animal DNA DNA vaccine Female Flow cytometry gp100 Melanoma Antigen - genetics gp100 Melanoma Antigen - immunology Laboratories Light Light scattering Melanoma Melanoma - therapy Mice, Inbred C57BL Plasmids Proteins Pulmonary Surfactant-Associated Protein D - genetics Pulmonary Surfactant-Associated Protein D - metabolism Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - immunology Sensors Studies Surfactant protein D Survival Analysis Treatment Outcome Tumors Vaccines Vaccines, DNA - administration & dosage Vaccines, DNA - genetics Vaccines, DNA - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • DNA vaccine technology fusing cancer antigens to CD40L soluble multi-trimers. • Allows targeting of vaccine antigens to dendritic cells in situ. • Activates and matures dendritic cells. • Vaccine induces an anti-tumor immune response when combined with IL-12 and GM-CSF.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2015.07.081